What the programme covers
Real-world imaging can support retrospective research, endpoint exploration, biomarker development and cohort characterization when the clinical question, source population and evidence limitations are explicit. MedCorpora's role is governed data sourcing and engineering rather than making clinical or regulatory claims.
What a useful specification includes
A defensible request defines the clinical task, source evidence and acceptance criteria before patient-level data moves. The exact fields and thresholds depend on the intended model claim.
- Disease area, research question and intended analysis
- Imaging modality, protocol and time points
- Treatment, pathology, report or outcome linkage
- Population, care setting and geography
- Reference-standard and reviewer requirements
- Permitted use, analysis environment and retention
Quality and validation controls
The programme describes how patients entered the source population, which evidence is observed, how imaging was acquired and which limitations affect interpretation. Derived variables retain source-level provenance.
- Cohort entry and index-date logic
- Imaging and clinical-event linkage
- Treatment and outcome timing
- Site, scanner and population distributions
- Missingness, censoring and provenance
Availability, rights and delivery
Feasible programmes can progress through permission, de-identification, curation and controlled delivery under programme-specific terms. A public capability page does not establish that a particular life-sciences cohort is already verified.
Public pages describe a sourcing and engineering capability, not guaranteed ready inventory. Each release remains subject to verified programme inventory, programme-specific authorization, privacy review, technical acceptance and buyer licence terms.
Questions, answered directly.
Can MedCorpora support biopharma imaging research?+
MedCorpora can assess buyer-defined imaging and linked-evidence requirements for biopharma research, subject to feasibility, permission and programme terms.
Can a cohort include treatment response?+
Potentially, when imaging time points, treatment records and response evidence are available and appropriately linked.
Does MedCorpora provide regulatory advice?+
No. Buyers should use qualified legal, privacy, clinical, statistical and regulatory professionals for applicable decisions.
Can US or international sites be assessed?+
Yes through buyer-specific feasibility; site availability and programme authority are not assumed in advance.